Enhanced biocompatibility of nanosized
contrast agent with high radiodensity and specific biodistribution is an important parameter for localized
tumor imaging and organ safety. Various nanoparticles, especially
gold nanorods (GNRs), have been applied for
tumor diagnosis. However, their toxicity, nonspecific biodistribution, and easy aggregation are critical issues in
cancer medicine. To avoid these issues, encapsulation of the GNRs in the core of nanoscopic mesoporous
silica (MS) under ambient conditions, yielding multifunctional nanomaterials for
cancer nanomedicine, is a recent and active development. Interestingly, GNR embedded MS nanohybrid (GNR-MS), though a promising material in nanomedicine, is rarely examined for
tumor diagnosis, in vivo toxicity, organ safety, contrast ability, and excretion. Herein, we report a systematic in vivo examination of
folic acid functionalized GNR-MS (GNR-MS-FA) for localized 4T1
breast tumor diagnosis, organ safety, and excretion using a one-time dose administration. The nanomaterials show good aqueous dispersibility, biocompatibility, high radiodensity, and
tumor specific targeting ability ( in vitro as well as in vivo). The in vivo
tumor diagnosis and specific biodistribution of injected nanomaterials clearly demonstrates their potential for the visualization of
tumors deep in the body of mice. In addition, all organs including the healthy glomerulus of the kidney are observed to be free of tissue
injuries thereby indicating the superior biocompatibility of the nanomaterials.